We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+13.36%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$1.76B
AUM Growth
+$158M
Cap. Flow
+$12.9M
Cap. Flow %
0.73%
Top 10 Hldgs %
26.37%
Holding
139
New
12
Increased
27
Reduced
23
Closed
3

Top Buys

Rank Stock Value
1
ELLI
Ellie Mae Inc
ELLI
+$22.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$13.2M
5
FIVN icon
FIVE9
FIVN
+$12.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$19M
2
BLUE
bluebird bio
BLUE
+$17M
3
SPLK
Splunk Inc
SPLK
+$10.6M
4
PFPT
Proofpoint, Inc.
PFPT
+$9.51M
5
KITE
Kite Pharma, Inc.
KITE
+$8.81M

Sector Composition

Rank Sector Weight
1 Healthcare 42.22%
2 Technology 17.94%
3 Consumer Discretionary 13.68%
4 Industrials 7.76%
5 Utilities 5.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWLO icon
51
Twilio
TWLO
$37.2B
$13.6M 0.77%
457,000
-208,000
-31% -$6.24M
VMC icon
52
Vulcan Materials
VMC
$32.3B
$13.2M 0.75%
110,000
– –
ACAD icon
53
Acadia Pharmaceuticals
ACAD
$4.61B
$12.6M 0.71%
334,700
– –
STML
54
DELISTED
Stemline Therapeutics, Inc.
STML
$12.1M 0.68%
1,086,400
– –
AKCA
55
DELISTED
Akcea Therapeutics Inc
AKCA
$11.6M 0.66%
+420,000
New +$7.77M
VYGR icon
56
Voyager Therapeutics
VYGR
$190M
$11.6M 0.66%
561,425
+261,425
+87% +$2.95M
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$31.9B
$10.6M 0.6%
90,000
– –
TSLA icon
58
Tesla
TSLA
$1.41T
$10.2M 0.58%
450,000
– –
PANW icon
59
Palo Alto Networks
PANW
$307B
$10M 0.57%
416,232
+26,232
+7% +$597K
SAGE
60
DELISTED
Sage Therapeutics
SAGE
$9.91M 0.56%
159,000
+78,000
+96% +$6.13M
WVE icon
61
Wave Life Sciences
WVE
$879M
$9.43M 0.53%
433,500
– –
MYOV
62
DELISTED
Myovant Sciences Ltd.
MYOV
$8.51M 0.48%
550,000
– –
PRTA icon
63
Prothena Corp
PRTA
$428M
$7.77M 0.44%
120,000
– –
CERN
64
DELISTED
Cerner Corp
CERN
$7.72M 0.44%
108,200
– –
NBIX icon
65
Neurocrine Biosciences
NBIX
$15.2B
$7.66M 0.43%
125,000
– –
SRPT icon
66
Sarepta Therapeutics
SRPT
$2.19B
$7.3M 0.41%
+161,000
New +$6.43M
DBVT
67
DBV Technologies
DBVT
$739M
$7.21M 0.41%
17,000
-3,700
-18% -$1.59M
XNCR icon
68
Xencor
XNCR
$1.77B
$7.17M 0.41%
313,000
-31,000
-9% -$688K
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$12.5B
$6.98M 0.4%
75,000
– –
EXR icon
70
Extra Space Storage
EXR
$29B
$6.55M 0.37%
82,000
+500
+0.6% +$38.9K
GWPH
71
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.45M 0.37%
63,500
– –
BOLD
72
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.3M 0.36%
225,000
– –
GBT
73
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.9M 0.33%
190,000
– –
LKFT
74
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$5.29M 0.3%
52,000
– –
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$5.24M 0.3%
275,000
– –
1 2
3
4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Eventide Asset Management held 139 positions worth $1.76B, up 9.9% from $1.61B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q3 2017 filing shows 12 new, 27 increased, 23 reduced and 3 closed positions. Its largest new stake was Ellie Mae Inc: 242,000 shares worth $19.9M. The largest sale was Loxo Oncology, Inc, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2017 buy was Ellie Mae Inc: 242,000 shares worth $19.9M.
  • Eventide Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $21.9M increase.
  • Eventide Asset Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $19M.
  • Eventide Asset Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $8.81M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.76B portfolio in Q3 2017.
  • Eventide Asset Management opened 12 new positions and closed 3 in Q3 2017.
  • Eventide Asset Management's portfolio value rose 9.9% quarter-over-quarter to $1.76B.

Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.